The real-world outcomes of Lutetium-177 PSMA-617 radioligand therapy in metastatic castration-resistant prostate cancer: Turkish Oncology Group multicenter study.
Int J Cancer
; 154(4): 692-700, 2024 Feb 15.
Article
in En
| MEDLINE
| ID: mdl-37818966
Full text:
1
Database:
MEDLINE
Main subject:
Prostate-Specific Antigen
/
Prostatic Neoplasms, Castration-Resistant
Type of study:
Clinical_trials
/
Observational_studies
Limits:
Humans
/
Male
Country/Region as subject:
Asia
Language:
En
Year:
2024
Type:
Article